A compound or a pharmaceutically acceptable salt or an enantiomer thereof, methods for modulating an androgen receptor-mediated function in a mammal in need of such modulation, for activating androgen receptor function in a mammal in need of such activation, to treat a condition in a mammal, and to treat osteoporosis in a mammal in need thereof, pharmaceutical composition, methods for increasing bone mineral density in a mammal in need of it, to reduce the risk of vertebral or nonvertebral fractures in a mammal in need of it, and to produce a bone modification marker in a mammal in need thereof, process for producing a pharmaceutical composition, and method for treating or preventing an arthritic condition in a mammal in need thereof

摘要

"COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ITS ENERGY, METHODS FOR MODULATING A FUNCTION MEDIATED BY ANDROGEN RECEIVER IN A MAMMER IN NEED OF SUCH MODULATION, AND ACTIVATING THE NECESSARY RECEIVER TREATMENT A CONDITION IN A MAMMER, AND TO TREAT OSTEOPOROSIS IN A MAMMER AT ITS NEED, PHARMACEUTICAL COMPOSITION, METHODS TO INCREASE BONE MINERAL DENSITY INTO THIS MISFER IN NEBRA NISIS IN THE NEED , AND TO PRODUCE A BONE MODIFICATION MARKER IN A MAMMALIAN NEEDED, PROCESS TO PRODUCE A PHARMACEUTICAL COMPOSITION, AND METHOD TO TREAT OR PREVENT AN ARTHRITIC CONDITION IN A MAMMALIAN NEEDED ". The compounds of structural formula I are androgen receptor (AR) modulators in a selective tissue manner. They are useful as androgen receptor agonists in bone and / or muscle tissue while antagonizing RA in a male patient's prostate or in a female patient's uterus. These compounds are therefore useful in treating conditions caused by androgen deficiency or that may be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone loss. following bone reconstructive surgery, sarcopenia, weakness, skin aging, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other haematopoietic disorders, inflammatory arthritis and joint repair, HIV emaciation, prostate cancer, cancerous cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.